
Zomedica Corp. (ZOM)
$
0.1
Key metrics
Financial statements
Free cash flow per share
-0.0200
Market cap
95.3 Million
Price to sales ratio
3.5675
Debt to equity
0.0102
Current ratio
10.8222
Income quality
0.3831
Average inventory
5.5 Million
ROE
-0.2816
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Zomedica Corp., a veterinary health company centered on addressing the unmet needs of clinical veterinarians, develops innovative products for companion animals. The company's operational efficiency is highlighted by its EBITDA ratio of -1.17. For the fiscal year 2024 Zomedica reported a gross profit of $17,318,000.00 underscoring its profitability from core operations. The company faced an income tax expense of -$1,331,000.00 reflecting its tax obligations, while also reporting depreciation and amortization expenses of $6,298,000.00 which indicate the wear and tear on its assets. With advancements in veterinary diagnostics, Zomedica has made significant strides through its TRUFORMA platform, providing point-of-care diagnostic products for dogs and cats. Moreover, the PulseVet service addresses various musculoskeletal issues in both horses and small animals. Collaborative agreements with Celsee, Inc. aim to develop and market liquid biopsy assays for cancer detection in companion animals, while a partnership with Seraph Biosciences, Inc. focuses on creating a novel pathogen detection system. Originally named Zomedica Pharmaceuticals Corp., the company rebranded to Zomedica Corp. in October 2020 and has its headquarters in Ann Arbor, Michigan, founded in 2015. In the stock market, Zomedica's shares are appealing to budget-conscious investors, priced affordably at $0.10. The stock's high average trading volume of 8,541,418.00 indicates strong liquidity, making it an attractive choice for potential investors. With a market capitalization of $95,349,137.00 Zomedica is classified as a small-cap player within the broader financial landscape. This positioning is significant, as Zomedica is a key player in the Drug Manufacturers - Specialty & Generic industry, contributing meaningfully to the market's overall dynamic. Additionally, the company operates within the Healthcare sector, driving ongoing innovation and growth, which further enhances its potential for future developments in veterinary health care.
Analysts predict Zomedica Corp. stock to fluctuate between $0.02 (low) and $0.20 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-03-04, Zomedica Corp.'s market cap is $95,349,137, based on 979,950,016 outstanding shares.
Compared to Eli Lilly & Co., Zomedica Corp. has a Lower Market-Cap, indicating a difference in performance.
To buy Zomedica Corp. (ZOM) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ZOM. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Revenue: $25,186,000 | EPS: -$0.04 | Growth: 102.30%.
Visit https://www.zomedica.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $0.80 (2021-08-26) | All-time low: $0.09 (2025-03-04).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News

seekingalpha.com
Zomedica Corp. (ZOMDF) Discusses Technology and Digital Innovation Driving Growth in Animal Health Transcript

accessnewswire.com
Agreement leverages existing infrastructure to add contract-based revenue, improve asset utilization, support long-term cash flow and create shareholder value through diversified markets ANN ARBOR, MI / ACCESS Newswire / January 22, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative diagnostic and therapeutic devices for equine and companion animals, today announced that it has entered into a contract manufacturing and service agreement with Rahm Sensor Development, a technology company advancing contact-free, multi-sensor monitoring solutions for high-risk environments. Under the agreement, Zomedica will manufacture Rahm's first commercial product, the Cell-Guardian ™, an advanced personnel monitoring device designed to improve safety and situational awareness in high-risk environments.

accessnewswire.com
January session to highlight Zomedica's expanding digital capabilities and long-term innovation strategy ANN ARBOR, MI / ACCESS Newswire / January 14, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative diagnostic and therapeutic devices for equine and companion animals, today announced the next installment of its "Fourth Friday at Four" investor webinar series, scheduled for Friday, January 23, 2026 at 4:00 p.m. Eastern Time.

accessnewswire.com
New platform improves workflow efficiency, strengthens clinical confidence, and supports Zomedica's long-term growth strategy ANN ARBOR, MI / ACCESS Newswire / December 30, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced the commercial launch of the VETGuardian PLUS monitor, the next generation of its Zero Touch™ patient monitoring platform for veterinary clinics. The VETGuardian PLUS monitor builds on the success of the original VETGuardian® system while adding new features that improve ease of use, workflow efficiency, and access to patient data.

seekingalpha.com
Zomedica Corp. (OTC:ZOMDF) Q3 2025 Earnings Call November 21, 2025 4:00 PM EST Company Participants Larry Heaton - President, CEO & Director Mike Zuehlke - Senior VP of Finance & Corporate Controller Presentation Unknown Executive Before we begin, I want to remind current and potential investors that we will be making various remarks about future expectations, plans and prospects that are considered forward-looking statements. There are risks that actual results may differ from these statements.

accessnewswire.com
November session to provide strategic context for Zomedica's product platforms featured in the previous Fourth Friday at Four Webinars ANN ARBOR, MI / ACCESS Newswire / November 11, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative diagnostic and therapeutic devices for equine and companion animals, today announced a special session of its "Fourth Friday at Four" investor webinar series. To accommodate the holiday calendar, this month's webinar will be held on the third Friday-November 21, 2025 at 4:00 p.m.

accessnewswire.com
Certification enhances global market readiness, reinforces quality systems, and supports Zomedica's long-term growth strategy ANN ARBOR, MI / ACCESS Newswire / November 6, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced that it has earned ISO 13485:2016 certification for its manufacturing and distribution operations in Plymouth, Minnesota and Roswell, Georgia. This milestone further cements Zomedica's commitment to quality, compliance, and global market readiness.

accessnewswire.com
Expanded agreement strengthens Zomedica's European presence, broadens product portfolio on the market, and positions the Company to capture growth in the multi-billion-dollar global veterinary diagnostics and therapeutic device markets ANN ARBOR, MI / ACCESS Newswire / October 14, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced that it has entered into an expanded distribution agreement with Grovet b.v., a leading equine health company based in the Netherlands.
accessnewswire.com
Agreement strengthens Canadian veterinarians' access to Zomedica's advanced therapeutic and monitoring solutions ANN ARBOR, MI / ACCESS Newswire / September 10, 2025 / Zomedica Corp. (OTCQB:ZOMDF), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, announced today that it has expanded its distribution agreement with UXR Inc., a leading Canadian animal health company focused on supporting the needs of veterinarians across Canada. Under the expanded agreement, UXR will become: Exclusive distributor of Zomedica's PulseVet® system in Canada and co-exclusive distributor of the system's consumable Trode accessories.

accessnewswire.com
Strategic partnership with Pioneer Veterinary Products Limited expands Zomedica's presence in the UK veterinary market through distribution of its leading point-of-care solutions ANN ARBOR, MI / ACCESS Newswire / September 3, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced a new distribution partnership in the United Kingdom with Pioneer Veterinary Products Limited, one of the region's most respected veterinary distributors. The agreement begins with the distribution of Zomedica's TRUFORMA® diagnostic platform throughout England, Scotland, Wales, and Northern Ireland, with the introduction of VETGuardian® remote monitoring technology planned at a later stage.
See all news